Quarterly Results: IFB Industries Ltd

Shital Jibhe / 28 Oct 2016

Quarterly Results: IFB Industries Ltd

IFB Industries’ standalone Q2FY17 numbers have come in above our estimate. Revenue has come in 8.7% higher than our estimate of Rs 404 cr yoy. EBITDA has come in 37.4% yoy higher than the estimated figure of Rs 24 cr.

Standalone Results Q2FY17: (Rs. in crore)


***EBITDA margin change in bps

IFB Industries’ standalone Q2FY17 numbers have come in above our estimate. Revenue has come in 8.7% higher than our estimate of Rs 404 cr yoy. EBITDA has come in 37.4% yoy higher than the estimated figure of Rs 24 cr. Net profit was 39.1% yoy higher than the estimate of Rs 13 cr.

Revenue for the quarter has increased 19.4% yoy to Rs 439 cr. This was driven by 22% yoy growth in home appliance segment.

Reported EBITDA has risen by 51.2% yoy to Rs 33 cr and EBITDA margins have expanded by 157 bps yoy to 7.5%. This was due to 20% yoy decline in purchase of stock-in-trade.

Net profit has surged 91% yoy to Rs 18 cr primarily led by a 117% yoy increase in other income.

Technical View: 

IFB Industries Ltd., has ended at Rs. 529.7, up by 4.15 points or 0.79% from its previous closing of Rs. 525.55 on the BSE. The scrip has opened at Rs. 526.25 and touched a high and low of Rs. 535 and Rs. 520.15 respectively. A total of 31972(NSE+BSE) shares were traded on the counter. The stock traded below its 50 DMA.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.